Sparking Sensation: A New Trial Targets Diabetic Nerve Damage

Current pharmacological defences against Painful Diabetic Neuropathy (PDN) are frequently breached, failing to provide adequate relief for millions. Enter the PDN-Sensory study, a robust multicentre, randomised controlled trial designed to evaluate a high-tech alternative: 10 kHz spinal cord stimulation (SCS). Building upon the promising SENZA-PDN study—which hinted that this therapy might improve sensory function—this new enquiry seeks to confirm whether bioelectronic intervention can do more than simply dull the pain.

The trial involves a head-to-head comparison between conventional medical management (CMM) and a hybrid approach combining CMM with a 10 kHz SCS implant. Participants suffering from chronic, intractable lower limb pain will be randomised, with the primary goal being a 50 per cent reduction in pain scores at the six-month mark. However, the scientific intrigue lies in the secondary endpoints. Researchers will analyse objective biological markers, specifically the modified Toronto Clinical Neuropathy Score (mTCNS) and intraepidermal nerve fibre density (IENFD), to detect tangible signs of neurological repair.

With an optional crossover design allowing patients to switch treatments after six months, the study prioritises patient welfare alongside data rigour. If the 10 kHz SCS system demonstrates an ability to restore nerve density and function, it could redefine the treatment landscape for diabetic complications, shifting the focus from mere symptom management to genuine neural restoration.